Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

Leukemia

Volumn 25, Issue 1, 2011, Pages 181-184

  Handgretinger, R ^a   Zugmaier, G ^b   Henze, G ^c   Kreyenberg, H ^d   Lang, P ^a   Von Stackelberg, A ^c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MICROMET AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BLINATUMOMAB; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; ETOPOSIDE; IMATINIB; MELPHALAN; PREDNISONE; THIOTEPA; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; CHILD; CONTINUOUS INFUSION; FASCICULATION; FATIGUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PEDIATRICS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREMOR; WHOLE BODY RADIATION;

EID: 78651290248     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.239     Document Type: Letter

References (8)

1. Loren AW, Porter DL. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 483-493.
2. Klingebiel T, Lang P, Schumm M, Koehl U, Bader P, Schwabe D et al. Experiences with haploidentical stem cell transplantation in children with acute lymphoblastic leukemia. Pathol Biol (Paris) 2005; 53: 159-161.
3. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377-384.
4. Jeha S. New therapeutic strategies in acute lymphoblastic leukemia. Semin Hematol 2009; 46: 76-88.
5. Baeuerle PA, Kufer P, Bargou R. BiTE: teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009; 11: 22-30.
6. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977.
7. Topp MS, Goekbuget N, Kufer P, Zugmaier G, Klinger M, Degenhard E et al. Blinatumomab (anti-CD19 bite) for targeted therapy of minimal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): update of an ongoing phase II study. Haematologica 2009; 94(Suppl 2): 195.
8. Lang P, Handgretinger R. Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant 2008; 42(Suppl 2): S54-S59.